Please assess the completion status of the following clinical trial:

Trial Title: Disturbed Sleep Model Study.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Body weight =50 kg and BMI within the range 18.5-29.9 kg/m2 inclusive~* Healthy as judged by responsible physician.~* No clinically significant abnormality identified on the medical or laboratory evaluation and 12-lead ECG;~* The subject shows a normal sleep pattern on the basis of the evaluation of both PSG screening nights. Normal sleep will be defined as follows: LPS (Latency to persistence Sleep) \<30min., SE (Sleep Efficiency) \>85%, apnea/ hypopnea index \< 10, periodic leg movements (PLM) with arousal index \< 10. The apnea/hypopnea index is defined as the number of apneas and hyponeas divided by the total sleep time (TST) expressed in hours. PLMI is defined as the number of periodic leg movements associated with arousals or awakening divided by the total sleep time (TST) expressed in hour.~Exclusion Criteria:~* A positive result for the pre-study urine drug/ alcohol breath screen.~* Abuse of alcohol.~* Subject complains of sleep disturbances and /or is receiving treatment for sleep disorders.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- ADBC sequence (Type: EXPERIMENTAL): In ADBC sequence A is Placebo, B is SB-649868 10 milligram (mg), C is SB-649868 30 mg, and D is Zolpidem 10 mg. Subject will receive placebo tablets, then two 5 mg tablets of SB-649868, then 25 mg and 5 mg tablet of SB-649868. There will be wash-out period of 7 days.
- BACD sequence (Type: EXPERIMENTAL): In BACD sequence subject will receive SB-649868 two tablets of 5 mg each (10 mg, B), Placebo tablets (A), SB-649868 two tablets of 25 mg and 5 mg (30 mg, C), and Zolpidem 10 mg (D). There will be wash-out period of 7 days.
- CBDA sequence (Type: EXPERIMENTAL): In CBDA sequence subject will receive SB-649868 two tablets of 25 mg and 5 mg (30 mg, C), SB-649868 two tablets of 5 mg each (10 mg, B), Zolpidem 10 mg (D) and Placebo tablet (A). There will be wash-out period of 7 days.
- DCAB sequence (Type: EXPERIMENTAL): In DCAB sequence subject will receive Zolpidem 10 mg (D), SB-649868 two tablets of 25 mg and 5 mg (30 mg, C), Placebo tablet (A), and SB-649868 two tablets of 5 mg each (10 mg, B). There will be wash-out period of 7 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).